- |||||||||| Azopt (brinzolamide ophthalmic suspension 1%) / Novartis, Lumigan (bimatoprost) / Senju, AbbVie
Journal, HEOR: Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. (Pubmed Central) - Aug 28, 2020
For the prostaglandin and β-adrenergic blocker fixed combinations, Ganfort was the most economical choice with its lower daily cost and per mmHg reduction cost. The results of this study could provide drug selection guidance from an economic perspective, but various factors should be considered when making a decision.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Review, Journal: Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata. (Pubmed Central) - Jul 18, 2020
Of the regenerative treatments, JAK inhibitors and bimatoprost stimulate repopulation of depleted cells in both diseases, intralesional injections of autologous concentrated platelet-rich plasma and minoxidil showed some benefit in AA, and phototherapy with narrowband UVB was shown to be effective especially in vitiligo. Finally, we discuss future treatments based on the mobilization of stem cells to regenerate anagen hair follicles in AA and intraepidermal melanocytes in vitiligo.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Review, Journal: Prevention and Treatment of Chemotherapy-Induced Alopecia. (Pubmed Central) - Jul 10, 2020
Therapy should always be modulated for the patient and no fixed protocol should be used. Trichoscopy and trichogram could be useful tools in supporting this treatment.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Clinical, Review, Journal: Discovery, characterization, and clinical utility of prostaglandin agonists for the treatment of glaucoma. (Pubmed Central) - Jul 5, 2020
This afforded the first marketed FP-class PG agonist analog (FP-PGA) ocular hypotensive agent, latanoprost. Since the introduction of latanoprost into clinical medicine to lower and control IOP, a number of additional FP-PGAs have been discovered, characterized and marketed, including travoprost, tafluprost, unoprostone isopropyl ester, and bimatoprost (an amide).
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Review, Journal: Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. (Pubmed Central) - Jul 5, 2020
NCX 470 was found more effective than bimatoprost in animal models of ocular hypertension and glaucoma. Selective EP receptor agonists (i.e., taprenepag isopropyl, omidenepag isopropyl; aganepag isopropyl) and non-selective prostanoid receptors agonists (i.e., ONO-9054, sepetaprost isopropyl) that concomitantly stimulate FP and EP receptors also hold promise.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Journal: Prostaglandin F2α Agonists Negatively Modulate the Size of 3D Organoids from Primary Human Orbital Fibroblasts. (Pubmed Central) - Jun 6, 2020
During adipogenesis, changes in HOF 3D organoid sizes, as well as their lipids stained by BODIPY and expression of the extracellular matrix (ECM) by immunolabeling and/or quantitative PCR, were studied in the presence or absence of either 100-nM bimatoprost acid or 100-nM prostaglandin F2α...Our present study indicates that PG analogs have the potential to modulate the ECM network within HOF 3D organoids. Thus, a 3D tissue culture system may be a suitable strategy for understanding the disease etiology of DUES.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, nitric oxide (NO)â€'donating bimatoprost analog (NCX 470) / Nicox
[VIRTUAL] Prospective Study of NCX 470 for IOP Lowering: Phase 2 Clinical Results (VM) - May 23, 2020 - Abstract #ASCRSASOA2020ASCRS-ASOA_1986;
Methods In this prospective, randomized, masked, phase 2 dose-response trial (Dolomites), 433 adult subjects with open-angle glaucoma or ocular hypertension who met IOP eligibility requirements at 3 time points at 2 eligibility visits received either NCX 470 ophthalmic solution (0.021%, 0.042%, or 0.065%) or latanoprost ophthalmic solution, 0.005%...Conclusion NCX 470 has the potential to be a valuable new IOP-lowering agent for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. The dose dependent IOP-lowering efficacy creates the potential for additional IOP lowering at higher doses to be evaluated in future trials.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Safety and Efficacy Assessment of Monoprost (clinicaltrials.gov) - Apr 2, 2020
P4, N=379, Completed,
Switching from BAK-preserved or PF bimatoprost-timolol to tafluprost-timolol reduced both signs and symptoms of ocular surface disease with no clinically relevant effect on IOP. Recruiting --> Completed
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Journal: Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma. (Pubmed Central) - Mar 19, 2020
The rabbit model failed to respond bimatoprost; thus, the efficacy studies need to be conducted on canines or human primates. The paper revealed the potential of using molecular imprinting technology to improve the uptake of bimatoprost and to achieve sustain release kinetics without altering the swelling, transmittance and folding endurance properties of the contact lens.
- |||||||||| Azopt (brinzolamide ophthalmic suspension 1%) / Novartis, Lumigan (bimatoprost) / Senju, Allergan
Further Characterization of a Spontaneous Glaucoma Model in Non-human Primates with Intraocular Pressure Lowering Agents (Exhibit Hall: Posterboard# A0103) - Mar 9, 2020 - Abstract #ARVO2020ARVO_1613;
Among them, brimonidine tartrate, a selective alpha-2 adrenergic receptor agonist, reduced IOP the most (21-/+ 4%).Conclusions A panel of IOP lowering agents with different mechanisms of action was evaluated in cynomolgus monkeys with spontaneous glaucoma and demonstrated different degree of efficacy in IOP lowering. It further evidences the similarity of this model to the human disease and its potential utilities in glaucoma research and novel therapeutics discovery and development.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Clinical, Journal: Adherence with Medical Therapy for Primary Open-Angle Glaucoma in Kenya - A Pilot Study. (Pubmed Central) - Mar 1, 2020
Participants with newly diagnosed open-angle glaucoma received a weighed bottle of Lumigan 0.01% with counselling on therapy...The signs of poor adherence based on both self-report (previous literature), and in this small-scale study of an objective measure suggest medication may not be the first-line treatment of choice in this environment. Our report does, however, raise the possibility that those patients who return for repeat prescriptions and review are indeed adhering to their treatment regimens.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Journal: Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension. (Pubmed Central) - Jan 30, 2020
The latanoprost group demonstrated a lower risk of discontinuing first-line therapy than the travoprost and bimatoprost groups. The results may assist ophthalmologists in determining the optimal management of this patient population with respect to treatment patterns.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Bimatoprost-induced histopathological and ultrastructural changes in rabbits eyelash follicle () - Jan 27, 2020 - Abstract #ESCRSWM2020ESCRS_WM_714;
Bimatoprost-induced eyelash changes are not restricted to increase eyelash length, thickness and pigmentation but also eyelashes increased in number within the same hair follicle and become stronger resisting pulling from the skin without any evidence of inflammatory cells within the specimens. These changes occurred as early as 1month of treatment arising thoughts about the possibility of using bimatoprost eye drops as a prophylaxis against madarosis associated with chemotherapy if it is started 1month before chemotherapy and continued afterwards mak- ing eyelashs stronger resisting falling.
- |||||||||| latanoprost / Generic mfg., Lumigan (bimatoprost) / Senju, Allergan, nitric oxide (NO)â€'donating bimatoprost analog (NCX 470) / Nicox
NCX 470, a Nitric Oxide Donating Bimatoprost Analog, Demonstrates Superiority to Latanoprost in Phase 2 Dolomites Clinical Trial (Woodrow Wilson Ballroom) - Jan 25, 2020 - Abstract #AGS2020AGS_361;
These changes occurred as early as 1month of treatment arising thoughts about the possibility of using bimatoprost eye drops as a prophylaxis against madarosis associated with chemotherapy if it is started 1month before chemotherapy and continued afterwards mak- ing eyelashs stronger resisting falling. NCX 470 has the potential to be a valuable new IOP-lowering agent for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion date, Trial primary completion date: Bimatoprost as a Treatment for Graves' Orbitopathy (clinicaltrials.gov) - Jan 23, 2020
P1, N=3, Recruiting,
NCX 470 has the potential to be a valuable new IOP-lowering agent for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: May 2019 --> May 2021
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Journal: Synthesis of Ultrastable Gold Nanoparticles as a New Drug Delivery System. (Pubmed Central) - Jan 18, 2020
The ability of ultrastable gold nanoparticles to encapsulate bimatoprost, a drug for glaucoma treatment, is demonstrated...The impact of ultrastable gold nanoparticles on wound healing dynamics is assessed on tissue engineered corneas. These results highlight the potential of ultrastable gold nanoparticles as a drug delivery system in ocular therapy.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan, Zioptan (tafluprost) / Santen, Merck (MSD)
Reimbursement, Journal, Medicare: Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D. (Pubmed Central) - Jan 5, 2020
Simultaneously, the prices and total expenditure on these medications are increasing yearly. Physicians should be cognizant of this price variation for these expensive and chronically used drugs and should educate patients to optimize their Part D supplemental plan.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan, Zioptan (tafluprost) / Santen, Merck (MSD)
Journal: Effect of Topical Prostaglandin F2α Analogs on Selected Oxidative Stress Parameters in the Tear Film. (Pubmed Central) - Jan 4, 2020
The TP concentrations in the groups L, L+BAC, and B+BAC were statistically significantly higher in comparison with group C. The SOD and CAT activities in the groups L+BAC and B+BAC were statistically significantly higher when compared to group C. As compared to group C, AOPP and TOS were statistically significantly higher in all the study groups. OSI was found to be statistically significantly higher in the groups L+BAC, T, and B+BAC in comparison with group C. Use of topical PGAs by the patients with ocular hypertension or primary open-angle glaucoma is associated with increased oxidative stress in the tear film which is additionally exacerbated by the presence of BAC in the formulation.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Preclinical, Journal: Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation. (Pubmed Central) - Jan 1, 2020
Presence of significant diffuse fluorescence in confocal microscopy of internal eye tissues post-in vivo application, as subconjunctival implant, even after 2 month and eye drops upto1 week provide direct evidence of successful sustained delivery. We thus provide an improved modality for antiglaucoma medication in patients who are challenged to adhere to a regimen of daily eye drops.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Clinical, Journal: Analysis of Bimatoprost-Induced changes on Rabbits eyelash Follicle: Clinical and Electron microscopic study. (Pubmed Central) - Dec 13, 2019
Bimatoprost-induced eyelash changes were not restricted to increased eyelash length, thickness, and pigmentation but also showed increased number of eyelashes within the same hair follicle which were stronger and could resist pulling from the skin without any evidence of inflammatory cells within the specimens. These changes occurred as early as 1 month of treatment, giving rise to thoughts about the possibility of using bimatoprost eye drops as a prophylaxis against madarosis associated with chemotherapy if it is started 1 month before chemotherapy and continued afterwards, making eyelashes stronger and resistant to falling out.
|
